Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 16/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 16/20 | 0.44 |
| ▸ | CDC42BPB | Q9Y5S2 | 16/20 | 0.44 |
| ▸ | AKT2 | P31751 | 1/20 | 0.37 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | CDC42BPA | Q5VT25 | 3/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21177443 | 0.99 | ROCK2 (0.44) | ROCK2ROCK1CDC42BPBAKT2PRKCA | |
| SCHEMBL21190143 | 0.92 | ROCK2 (0.36) | ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL21190142 | 0.90 | ROCK2 (0.42) | ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL21189975 | 0.90 | ROCK2 (0.40) | ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL21190173 | 0.90 | ROCK1 (0.43) | ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL21189967 | 0.90 | ITGB2 (0.38) | ROCK2ROCK1CDC42BPB | |
| SCHEMBL21190153 | 0.89 | ROCK2 (0.41) | ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL21177471 | 0.89 | ROCK1 (0.39) | ROCK2ROCK1CDC42BPBCDC42BPAHDAC10 | |
| SCHEMBL21190038 | 0.88 | LRRK2 (0.43) | ROCK2ROCK1CDC42BPB | |
| Formic Acid SCHEMBL21177218 | 0.87 | ITGB2 (0.37) | ROCK2ROCK1CDC42BPB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200171030-A1 | DUAL INHIBITORS OF ALK5 AND P38A MAP KINASE | INTEGRAL BIOSCIENCES PRIVATE LTD (IN) | 2020-06-04 | — | — | US | claimed |
| WO-2019142128-A1 | DUAL INHIBITORS OF ALK5 AND P38Α MAP KINASE | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2019-07-25 | — | — | WO | claimed |
| US-20200171030-A1 | DUAL INHIBITORS OF ALK5 AND P38A MAP KINASE | INTEGRAL BIOSCIENCES PRIVATE LTD (IN) | 2020-06-04 | — | — | US | disclosed |
| US-20200171030-A1 | DUAL INHIBITORS OF ALK5 AND P38A MAP KINASE | INTEGRAL BIOSCIENCES PRIVATE LTD (IN) | 2020-06-04 | — | — | US | disclosed |
| WO-2019142128-A1 | DUAL INHIBITORS OF ALK5 AND P38Α MAP KINASE | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019142128-A1 | DUAL INHIBITORS OF ALK5 AND P38Α MAP KINASE | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200171030-A1 | DUAL INHIBITORS OF ALK5 AND P38A MAP KINASE | MAP2K2, MAP2K5, MAP2K1 | ROCK2 160/4885ROCK1 159/4885CDC42BPB 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.